Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2014-03-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion by the independent directors of the company regarding the use of company funds by controlling shareholders and related parties, as well as the company's external guarantees. It references regulatory notices from the China Securities Regulatory Commission and confirms the absence of fund occupation and external guarantees as of a specific date. The document is short (530 characters) and serves as a formal attestation or certification rather than a full financial report or audit. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which covers attestations and compliance-related statements that do not fit other categories.
2014-03-18 Chinese
独立董事（张红英）述职报告
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of 普洛药业股份有限公司 (Puluo Pharmaceutical Co., Ltd.) covering activities and opinions related to the company's board meetings, shareholder meetings, and various corporate governance matters during the year 2013. It includes attendance records, independent opinions on financial and governance issues, and oversight activities related to the annual report and other corporate actions. The content is focused on the independent director's duties, opinions on company matters, and governance oversight rather than the full annual financial report itself. This type of document aligns with Board/Management Information (MANG) filings, which cover announcements and reports related to board activities and management changes or opinions. It is not an Annual Report (10-K) or Audit Report (AR) because it does not contain full financial statements or audit opinions but rather the independent director's report on their duties and observations. Therefore, the correct classification is MANG with high confidence.
2014-03-17 Chinese
第五届监事会第十七次会议决议
Board/Management Information Classification · 95% confidence The document is a resolution from the Supervisory Board meeting of a company, discussing approval of various reports including the 2013 Annual Report, Supervisory Board Work Report, Financial Work Report, profit distribution plan, and other related corporate governance matters. It also includes nomination of candidates for the next Supervisory Board and approval of audit unit appointment and non-public stock issuance plans. The document is a meeting resolution and not the actual annual report or financial statements. It is not a call transcript, earnings release, or capital update. It is not a simple announcement of a report publication but a detailed meeting decision document. Therefore, it fits best under Board/Management Information (MANG) as it relates to supervisory board decisions and management matters.
2014-03-17 Chinese
关于授权董事长进行理财投资的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the company 普洛药业股份有限公司 regarding the authorization of the chairman to conduct financial investment using the company's idle funds. It details the investment scope, amount, risk analysis, and control measures. The document is short (1081 characters) and does not contain financial statements or detailed financial data. It is an announcement about a financing-related decision rather than a full financial report or detailed capital update. Given the content focuses on financing activities (investment of idle funds) and authorization, it fits best under Capital/Financing Update (CAP).
2014-03-17 Chinese
关于2014年公司为控股子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by 普洛药业股份有限公司 regarding the company's provision of guarantees for its controlling subsidiaries in 2014. It details the guarantee plan, the subsidiaries involved, their business scope, financial performance, and the total guarantee amount. It also includes independent directors' opinions on the guarantees and mentions that the proposal will be submitted to the shareholders' meeting for approval. The document is an announcement of a specific corporate action related to financing guarantees rather than a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis typical of annual or interim reports. The document length is 3685 characters, which is relatively short and focused on a specific topic. Therefore, it fits best into the category of Capital/Financing Update (CAP), as it updates on the company's financing-related activities (providing guarantees).
2014-03-17 Chinese
独立董事（蒋岳祥）述职报告
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of 普洛药业股份有限公司 (Puluo Pharmaceutical Co., Ltd.) covering activities and opinions related to the company's board meetings, shareholder meetings, and various corporate governance matters during the year 2013. It includes attendance records, independent opinions on financial and governance issues, and compliance with laws and regulations. The content focuses on the director's duties, oversight, and governance-related opinions rather than financial results or earnings. There is no indication that this is a full annual report (10-K), audit report, earnings release, or other financial statement. Instead, it is a management/board-related report detailing the independent director's work and opinions, which fits the category of Board/Management Information (MANG). The document length (9691 characters) and detailed content support this classification rather than a brief announcement or regulatory filing. Therefore, the best classification is MANG with high confidence.
2014-03-17 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.